相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PIK3CA Mutations Are Associated With Decreased Benefit to Neoadjuvant Human Epidermal Growth Factor Receptor 2-Targeted Therapies in Breast Cancer
Ian J. Majewski et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
COSMIC: exploring the world's knowledge of somatic mutations in human cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2015)
Breast Cancer Statistics, 2013
Carol DeSantis et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Abstract 2050: BAY 1125976, a highly selective and potent allosteric AKT1/2 inhibitor, for the treatment of cancers with aberrations in the PI3K-AKT-mTOR pathway.
Oliver Politz et al.
CANCER RESEARCH (2014)
Patients and Methods of the PATH Biobank - A Resource for Breast Cancer Research
A. Waldmann et al.
GEBURTSHILFE UND FRAUENHEILKUNDE (2014)
Targeting Activated Akt with GDC-0068, a Novel Selective Akt Inhibitor That Is Efficacious in Multiple Tumor Models
Jie Lin et al.
CLINICAL CANCER RESEARCH (2013)
PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System
Julia A. Beaver et al.
CLINICAL CANCER RESEARCH (2013)
PIK3CA-AKT pathway mutations in micropapillary breast carcinoma
Ellen Flatley et al.
HUMAN PATHOLOGY (2013)
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing
Garrett M. Frampton et al.
NATURE BIOTECHNOLOGY (2013)
PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs
R. L. Ross et al.
ONCOGENE (2013)
Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers
O. Brouckaert et al.
ANNALS OF ONCOLOGY (2012)
Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes
Sandrine Boyault et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancers
Libero Santarpia et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Detection of Tumor PIK3CA Status in Metastatic Breast Cancer Using Peripheral Blood
Michaela J. Higgins et al.
CLINICAL CANCER RESEARCH (2012)
Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer
M. Arnedos et al.
EUROPEAN JOURNAL OF CANCER (2012)
Mucinous breast carcinomas lack PIK3CA and AKT1 mutations
Elizabeth L. Kehr et al.
HUMAN PATHOLOGY (2012)
Phosphatidylinositol-3-kinase pathway mutations are common in breast columnar cell lesions
Megan L. Troxell et al.
MODERN PATHOLOGY (2012)
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Barry R. Davies et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers
Geraldine Perkins et al.
PLOS ONE (2012)
Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers
Chaitali Parikh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A Mosaic Activating Mutation in AKT1 Associated with the Proteus Syndrome
Marjorie J. Lindhurst et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma
Jennifer Dunlap et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer
Ruth E. Board et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast
Megan L. Troxell et al.
MODERN PATHOLOGY (2010)
MK-2206, an Allosteric Akt Inhibitor, Enhances Antitumor Efficacy by Standard Chemotherapeutic Agents or Molecular Targeted Drugs In vitro and In vivo
Hiroshi Hirai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Diverse somatic mutation patterns and pathway alterations in human cancers
Zhengyan Kan et al.
NATURE (2010)
Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations
J. Lauring et al.
ONCOGENE (2010)
The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas
K. Shoji et al.
BRITISH JOURNAL OF CANCER (2009)
Identification of Novel Gene Amplifications in Breast Cancer and Coexistence of Gene Amplification with an Activating Mutation of PIK3CA
Mitsutaka Kadota et al.
CANCER RESEARCH (2009)
PIK3CA Mutation Associates with Improved Outcome in Breast Cancer
Kevin Kalinsky et al.
CLINICAL CANCER RESEARCH (2009)
Molecular Mechanism of an Oncogenic Mutation That Alters Membrane Targeting: Glu17Lys Modifies the PIP Lipid Specificity of the AKT1 PH Domain
Kyle E. Landgraf et al.
BIOCHEMISTRY (2008)
Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
M. S. Kim et al.
BRITISH JOURNAL OF CANCER (2008)
Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
Katherine Stemke-Hale et al.
CANCER RESEARCH (2008)
Circulating mutant DNA to assess tumor dynamics
Frank Diehl et al.
NATURE MEDICINE (2008)
AKT1E17K in human solid tumours
F. E. Bleeker et al.
ONCOGENE (2008)
Following the tracks of AM gene
Paraskevi Vogiatzi et al.
CANCER BIOLOGY & THERAPY (2007)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients
Maria Daniotti et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions
Frank Diehl et al.
NATURE METHODS (2006)
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
LH Saal et al.
CANCER RESEARCH (2005)
Activation of Akt-1 (PKB-α) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion
JN Hutchinson et al.
CANCER RESEARCH (2004)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
分享论文
